AIM ImmunoTech Inc.

What they do

AIM ImmunoTech is focused on the research and development of Ampligen (rintatolimod), a double-stranded RNA and highly selective TLR3 agonist immuno-modulator. The company's primary strategic focus is treating late-stage pancreatic cancer, with additional exploratory programs in infectious diseases like Ebola. It generates minimal revenue from its Ampligen Cost Recovery Program, which provides Ampligen to patients on a cost-recovery basis.

Revenue drivers

• Ampligen Cost Recovery Program — Only source of revenue; recognized $88,000 in 2025, down from $170,000 in 2024, reflecting fluctuating patient participation.

Recent performance

For the second quarter of 2026, AIM reported a net loss of approximately $3.8 million, or $(0.43) per share, compared to a net loss of $2.8 million, or $(3.68) per share, in the same period of 2025. R&D expenses decreased to $589,000 from $1.2 million, while G&A expenses increased to $2.9 million from $1.5 million. As of June 30, 2026, cash and cash equivalents were $9.9 million, up from approximately $3.0 million at year-end 2025. Annual net loss for 2025 was $14.0 million, an improvement from $17.3 million in 2024.

Strategy

Management states a clear and disciplined strategy centered on advancing Ampligen in pancreatic cancer, with an anticipated Phase 3 study in metastatic pancreatic cancer. The company is also pursuing select government-funded infectious disease initiatives, such as Ebola, to secure non-dilutive funding. It completed enrollment and dosing in the Phase 2 DURIPANC trial and engaged Thermo Fisher Scientific's PPD business to support the Phase 3 trial design. Recent financing transactions strengthened its balance sheet and the company regained full compliance with NYSE American listing standards.

Risks

• Going concern risk — The company has a history of losses and substantial doubt about its ability to continue as a going concern; the financial statements assume going concern.
• NYSE American delisting risk — The company was not in compliance with the Exchange's stockholders' equity rule (minimum $6,000,000) and must regain compliance by June 11, 2026, or face delisting.
• Clinical and regulatory risk — Ampligen has not been approved for any indication, and success in Phase 2 does not guarantee positive Phase 3 results or regulatory approval.
• Dependence on capital raises — The company relies on raising additional capital through offerings and at-the-market sales; its ability to continue operations depends on obtaining sufficient funding.

Outlook

Management expects DURIPANC data on clinical benefit in Q1 2027 and Overall Survival data in Q3 2027. They believe this data will support a pivotal Phase 3 trial design, citing a median Overall Survival of 34.8 months from a Named Patient Program compared to 12.5 months for historical controls. Government-funded Ebola initiatives are planned, but the company maintains pancreatic cancer as its primary strategic focus.